Ajovy
(Fremanezumab)ApprovedMonoclonal antibody
TevaFremanezumab is used to prevent migraines by reducing how often they occur. It works by blocking a protein in the brain that is involved in migraine pain.[2] Ajovy is currently approved and in use across 10 indications[4].[1]
Ajovy is one of 199 monoclonal antibody programs targeting Hyperprolactinemia. It is currently in Approved.
10
Indications
29
Total Trials
6
Active Trials
198
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Ajovy
TevaApproved
Daliresp
AstraZenecaPhase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Psilocybin
COMPASS PathwaysPhase 3
Fetzima
AbbViePhase 3
Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
ALKS 37
AAlkermes, Inc.
Phase 3
Desvenlafaxine SR
PfizerPhase 3
Brenipatide
Eli LillyPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine20 trials
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
Active, not recruiting·—·Phase 4·NCT06173661·72 enrolled
Show 17 more trials
Fremanezumab, Migraine and Sleep
Terminated·—·Phase 4·NCT04693533·22 enrolled
Cluster headache3 trials
Major Depressive Disorder1 trial
Headache1 trial
3 more indications
Interstitial Cystitis1 trial
Regulatory
FDA Approval Timeline[5]
Sep 14, 2018
AJOVY
BLA BLA761089
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ajovy drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Fremanezumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]